jRCT2031230637招募中不适用
A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients with Solid Tumors Likely to Express CLDN18.2 (ELVCAP-002-01)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 主要终点
- The incidence rate of dose limiting toxicities (DLT) during the first 21-day cycle of EO-3021 treatment
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Availability of tumor tissue (archived and fresh tumor biopsy, if medically feasible)
- •Select advanced or metastatic solid tumor that is likely to express CLDN18.2 such as gastric/GEJ, pancreatic and esophageal cancer
- •>= 18 years of age
- •ECOG performance status (PS) 0 or 1 at Screening
- •Progressed on or after standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy
- •Have at least one measurable extra-cranial lesion as defined by RECIST v1.1
- •Adequate organ function
- •Life expectancy > 12 weeks
- •Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent
- •Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following study completion
排除标准
- •Pregnant or breastfeeding
- •Symptomatic or untreated brain metastases
- •Have previously received CLDN18.2 antibody drug conjugates (ADCs) or any ADC containing an auristatin payload (prior monoclonal antibody against CLDN18.2 may be eligible)
- •Have peripheral neuropathy Grade >= 2
- •Have history of non-infectious pneumonitis/interstitial lung disease
- •Have diagnosis of another malignancy, or history of systemic treatment for invasive cancer within last 3 years. Note: Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. Diagnosis of non-melanoma skin cancer, carcinoma in situ of the cervix or breast, or noninvasive tumor does not affect eligibility
- •Have active ocular surface disease at baseline (based on screening ophthalmic examination)
- •Have serious concurrent illness or clinically relevant active bacterial, fungal or viral infection
- •Have previous hypersensitivity to any known components of EO-3021 or history of severe infusion reaction or hypersensitivity (CTCAE Grade 3 or higher) with monoclonal antibody treatment
- •Clinically significant cardiac disease, including but not limited to symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 6 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes)
- •Have history of allogenic hematopoietic stem cell transplantation or solid organ transplantation with ongoing systemic immunosuppressive therapy
- •Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the Investigator
结局指标
主要结局
The incidence rate of dose limiting toxicities (DLT) during the first 21-day cycle of EO-3021 treatment
时间窗: first 21-day cycle of EO-3021 treatment
The incidence rate of dose limiting toxicities (DLT)
Number of patients with treatment emergent adverse events
Number of patients with treatment emergent adverse events
Number of patients with serious adverse events
Number of patients with serious adverse events
Number of patients with clinically significant changes to vital signs
Number of patients with clinically significant changes to vital signs
Number of patients with clinically significant changes in laboratory tests
Number of patients with clinically significant changes in laboratory tests
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Phase 1 Study of E7090 in Subjects With Solid TumorJPRN-jRCT2080222689Eisai Co., Ltd.40
未知
3 期
ong-term study of HP-3150 in patients with cancer pain.Cancer painJPRN-jRCT2080222906Hisamitsu Pharmaceutical Co., Inc
未知
3 期
ong-term study of TA-8317 in patients with cancer breakthrough paiCancer breakthrough painJPRN-jRCT2080220302Mitsubishi Tanabe Pharma Corporation
已完成
不适用
Oncologic outcome for elderly patients with endometrial cancer who underwent minimally invasive surgery: retrospective multicenter trialJPRN-UMIN000043709Osaka Medical College200
尚未招募
2 期
A clinical study to assess the Feasibility Study of the Tumour Specific Electroporation (TSE) Technique in Patients with Locally Advanced or Recurrent Head & Neck CancerCTRI/2022/09/045315India Sweden Healthcare Innovation Centre